STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews
Novo Nordisk to halve U.S. list price of Wegovy from 2027
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday
What to Know About Trying to Conceive If You’re Taking a GLP-1
Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.
Satisfaction With Semaglutide Driven by Effective Weight Loss
FRIDAY, Feb. 20, 2026 — Satisfaction with semaglutide (Ozempic) is mainly driven by effective weight loss despite gastrointestinal side effects, according to a study published in the February issue of the Journal of Medical Internet…
Tirzepatide Use Linked to Lower Risk for Diabetic Retinopathy
FRIDAY, Feb. 20, 2026 — For patients with diabetes and overweight or obesity, tirzepatide use is associated with a lower incidence of new or progressive diabetic retinopathy (DR) and fewer complications, according to a study published online Jan…
Midsize Bodies Were Finally Going Mainstream—Then GLP-1s Came Along
Could weight-loss drugs shrink the body representation we’ve spent decades seeking?
Study finds tirzepatide cuts alcohol intake by more than half in rodents
For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings are considered relevant in the search for new treatments for alcohol use disorder. Researchers at the University of Gothenburg have previously demonstrated that semaglutide, found in the diabetes and weight-loss drugs Ozempic and Wegovy, reduces alcohol consumption in rats. In the current study, published in the journal eBioMedicine, the focus shifts to tirzepatide and Mounjaro.
Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes
Tirzepatide may help lower the risk of diabetic retinopathy, a diabetes complication that can lead to vision loss. Douglas Sacha/Getty Images
Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of diabetic retinopathy.
This diabetes complication occurs when high blood sugar levels damage the blood vessels in the retina at the back of the eye.
Hims reports 2025 earnings, shares details on GLP-1 pill decisions
Hims & Hers said it pulled its controversial weight loss pill after discussions with “ecosystem stakeholders” during its fourth-quarter earnings call on Monday.
The comments come after Hims offered, then
STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.